EUVIMEDEUVIMED entdecken
VergleichsstudieKohortenstudieOpen Access · CC BY-NC 3.0

Sugammadex vs Neostigmine for Reversal of Neuromuscular Blockade and Association with Postoperative Atelectasis After Video-Assisted Thoracoscopic Surgery: A Propensity Score-Matched Cohort Study

Kuo-Chuan Hung iD, Hsiu-Lan Weng, Jheng-Yan Wu iD, Chih-Wei Hsu iD, Chih-Ping Yang, Yi-Chen Lai, I-Wen Chen iD

Drug Design, Development and Therapy · 2026

DOI: 10.2147/dddt.s593657 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Drug Design, Development and Therapy, 2026. Verfasst von Kuo-Chuan Hung und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology, Chi Mei Medical Center, Tainan, Taiwan. Hauptthemen laut MEDLINE: Sugammadex, Neostigmine, Pulmonary Atelectasis, Thoracic Surgery, Video-Assisted. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Postoperative atelectasis remains a significant concern after video-assisted thoracoscopic surgery (VATS). This study aimed to evaluate the association between sugammadex use and postoperative atelectasis in patients who underwent VATS. Patients and methods: From the TriNetX Global Collaborative Network (2016-2024), adults undergoing elective VATS who received rocuronium reversed with either sugammadex or neostigmine were identified. The primary outcome was atelectasis within 30 days, identified using the administrative ICD diagnostic codes recorded in the TriNetX database. The secondary outcomes included pneumonia, acute respiratory failure, pneumothorax, sepsis, and major adverse cardiovascular events (MACEs). Outcomes were additionally assessed at 7-day and 90-day intervals.

Results

After propensity score matching (1:1), 7345 patients were analyzed per group. Sugammadex exposure was associated with lower odds of atelectasis at 30 days (odds ratio [OR], 0.79; 95% confidence interval [CI], 0.72-0.86; P < 0.001), corresponding to an absolute risk reduction of 3.3% (15.3% vs 18.6%). The association remained consistent at 7-day (OR, 0.75) and 90-day (OR, 0.81) follow-ups. Time-to-event analysis demonstrated a lower hazard of atelectasis (hazard ratio, 0.82; 95% CI, 0.76-0.88). Sugammadex was also associated with reduced pneumothorax (OR, 0.90) and MACEs (OR, 0.75), but not with pneumonia, respiratory failure, or sepsis. Subgroup analyses revealed significant interactions between sex (P = 0.003) and obesity status (P = 0.047), with more pronounced associations in males and non-obese patients.

Conclusion

Sugammadex use was associated with a reduced postoperative atelectasis risk in patients undergoing VATS. Prospective randomized trials are warranted to confirm these findings and establish causality.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SugammadexNeostigminePulmonary AtelectasisThoracic Surgery, Video-AssistedNeuromuscular BlockadePostoperative ComplicationsHumansMaleFemaleMiddle AgedPropensity ScoreCohort StudiesAged

Stichwörter der Autor:innen

atelectasisneostigmineneuromuscular blockadepostoperative pulmonary complicationssugammadexvideo-assisted thoracoscopic surgery

Substanzen

SugammadexNeostigmine

Autor:innen und Institutionen

  • Department of Anesthesiology, Chi Mei Medical Center, Tainan, Taiwan.
  • School of Medicine, College of Medicine, National Sun Yat-Sen University, Kaohsiung, Taiwan.
  • Department of Anesthesiology, E-Da Hospital, I-Shou University, Kaohsiung, Taiwan.
  • Department of Nutrition, Chi Mei Medical Center, Tainan, Taiwan.
  • Department of Psychiatry, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan.
  • Department of Anesthesiology, Chi Mei Medical Center, Liouying, Tainan, Taiwan.

ORCID-Profile: Kuo-Chuan Hung, Jheng-Yan Wu, Chih-Wei Hsu, I-Wen Chen

Zitieren

APA

Hung, K. C., Weng, H. L., Wu, J. Y., Hsu, C. W., Yang, C. P., Lai, Y. C., & Chen, I. W. (2026). Sugammadex vs Neostigmine for Reversal of Neuromuscular Blockade and Association with Postoperative Atelectasis After Video-Assisted Thoracoscopic Surgery: A Propensity Score-Matched Cohort Study. Drug Design, Development and Therapy. https://doi.org/10.2147/dddt.s593657

Vancouver

Hung KC, Weng HL, Wu JY, Hsu CW, Yang CP, Lai YC, et al. Sugammadex vs Neostigmine for Reversal of Neuromuscular Blockade and Association with Postoperative Atelectasis After Video-Assisted Thoracoscopic Surgery: A Propensity Score-Matched Cohort Study. Drug Design, Development and Therapy. 2026. doi:10.2147/dddt.s593657

BibTeX
@article{Hung2026,
  author = {Hung, Kuo-Chuan and Weng, Hsiu-Lan and Wu, Jheng-Yan and Hsu, Chih-Wei and Yang, Chih-Ping and Lai, Yi-Chen and Chen, I-Wen},
  title = {Sugammadex vs Neostigmine for Reversal of Neuromuscular Blockade and Association with Postoperative Atelectasis After Video-Assisted Thoracoscopic Surgery: A Propensity Score-Matched Cohort Study},
  journal = {Drug Design, Development and Therapy},
  year = {2026},
  doi = {10.2147/dddt.s593657}
}
Kostenlos starten →